2-乙氧基-4-甲基苯磺酰胺 | 199590-76-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-乙氧基-4-甲基苯磺酰胺
• 英文名称: 2-Ethoxy-4-methyl-benzenesulfonamide
• 英文别名: 2-Ethoxy-4-methylbenzenesulfonamide
• CAS: 199590-76-6
• 化学式: C₉H₁₃NO₃S
• 分子量: 215.273
• InChiKey: KHPGWXDFJBBHPD-UHFFFAOYSA-N

物化性质

• 沸点：
  383.0±52.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  77.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-乙氧基-4-甲基苯磺酰胺 、 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成
  参考文献：
  名称：

  The design and synthesis of a novel series of indole derived selective ETA antagonists

  摘要：

  Conformational constraint has been used as the key design element in the identification of a series of potent and selective ETA antagonists. The most potent antagonist, 32, (ETA IC50 = 0.55 nM) is 722-fold selective over the ETB receptor, as measured by binding experiments. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00660-6

文献信息

• [EN] INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'INDOLE UTILES EN TANT QU'ANTAGONISTES DU RECEPTEUR DE L'ENDOTHELINE
  申请人：PFIZER INC.

  公开号：WO1997043260A1

  公开（公告）日：1997-11-20

  (EN) Compounds of formula (I), and their pharmaceutically acceptable derivatives, wherein R1 and R2 are optional substituents and independently represent C1-6 alkyl, C2-6 alkenyl [optionally substituted by CO2H or CO2(C1-6 alkyl)], C2-6 alkynyl, halogen, C1-3 perfluoroalkyl, (CH2)mAr1, (CH2)mHet1, (CH2)mCONR7R8, (CH2)mCO2R8, O(CH2)qCO2R8, (CH2)mCOR8, (CH2)mOR8, O(CH2)pOR8, (CH2)mNR7R8, CO2(CH2)qNR7R8, (CH2)mCN, S(O)nR8, SO2NR7R8, CONH(CH2)mAr1 or CONH(CH2)mHet1; R3 represents H, C1-6 alkyl, (CH2)pNR9R10, SO2R10, SO2NR9R10, (CH2)mCOR10, C2-6 alkenyl, C2-6 alkynyl, (CH2)mCONR9R10, (CH2)mCO2R10, (CH2)pCN, (CH2)pR10 or (CH2)pOR10; R4 represents H or C1-6 alkyl; R5 represents H or OH; R6 represents phenyl optionally fused to a heterocyclic ring, the group as a whole being optionally substituted; R7-10 are fully defined herein and may independently represent Ar2 or Het2; Z represents CO2H, CONH(tetrazol-5-yl), CONHSO2O(C1-4 alkyl), CO2Ar3, CO2(C1-6 alkyl), tetrazol-5-yl, CONHSO2Ar3, CONHSO2(CH2)qAr3 or CONHSO2(C1-6 alkyl); Ar1-3 independently represent phenyl, naphthyl, or an aromatic heterocycle, which groups are optionally fused and optionally substituted; and Het1 and Het2 independently represent a non-aromatic heterocycle which is optionally substituted; are useful in the treatment of restenosis, renal failure and pulmonary hypertension.(FR) Composés de formule (I) et leurs dérivés acceptables sur le plan pharmaceutique. Dans ladite formule, R1 et R2 sont des substituants optionnels et représentent indépendamment alkyle C1-6, alcényle C2-6 [éventuellement substitué par CO2H ou CO2(alkyle C1-6)], alcynyle C2-6, halogène, perfluoroalkyle C1-3, (CH2)mAR1, (CH2)mHet1, (CH2)mCONR7R8, (CH2)mCO2R8, O(CH2)qCO2R8, (CH2)mCOR8, (CH2)mOR8, O(CH2)pOR8, (CH2)mNR7R8, CO2(CH2)qNR7R8, (CH2)mCN, S(O)nR8,SO2NR7R8, CONH(CH2)mAr1 ou CONH(CH2)mHet1; R3 représente H, alkyle C1-6, (CH2)pNR9R10, SO2R10, SO2NR9R10, (CH2)mCOR10, alcényle C2-6, alcynyle C2-6, (CH2)mCONR9R10, (CH2)mCO2R10, (CH2)pCN, (CH2)pR10 ou (CH2)pOR10; R4 représente H ou alkyle C1-6; R5 représente H ou OH; R6 représente phényle éventuellement fusionné à un noyau hétérocyclique, le groupe dans son intégralité étant éventuellement substitué; R7-10 sont intégralement définis dans la description et peuvent représenter indépendamment Ar2 ou Het2; Z représente CO2H, CONH(tétrazol-5-yle), CONHSO2O(alkyle C1-4), CO2Ar3, CO2(alkyle C1-6), tétrazol-5-yle, CONHSO2Ar3, CONHSO2(CH2)qAr3 ou CONHSO2(alkyle C1-6); Ar1-3 représente indépendamment phényle, naphtyle ou un hérétocycle non aromatique dont les groupes sont éventuellement fusionnés et substitués; et Het1 et Het2 représentent indépendamment un hétérocycle aromatique éventuellement substitué. Les composés selon l'invention sont utiles dans le traitement de la resténose, de l'insuffisance rénale et de l'hypertension pulmonaire.

  化合物公式（I）及其药学上可接受的衍生物，其中R1和R2为可选取代基团，独立地表示C1-6烷基，C2-6烯基[可选取代为CO2H或CO2（C1-6烷基）]，C2-6炔基，卤素，C1-3全氟烷基，（CH2）mAr1，（CH2）mHet1，（CH2）mCONR7R8，（CH2）mCO2R8，O（CH2）qCO2R8，（CH2）mCOR8，（CH2）mOR8，O（CH2）pOR8，（CH2）mNR7R8，CO2（CH2）qNR7R8，（CH2）mCN，S（O）nR8，SO2NR7R8，CONH（CH2）mAr1或CONH（CH2）mHet1；R3表示H，C1-6烷基，（CH2）pNR9R10，SO2R10，SO2NR9R10，（CH2）mCOR10，C2-6烯基，C2-6炔基，（CH2）mCONR9R10，（CH2）mCO2R10，（CH2）pCN，（CH2）pR10或（CH2）pOR10；R4表示H或C1-6烷基；R5表示H或OH；R6表示苯基，可选地融合到杂环环上，整个基团可选地取代；R7-10在此完全定义，可以独立地表示Ar2或Het2；Z表示CO2H，CONH（四唑-5-基），CONHSO2O（C1-4烷基），CO2Ar3，CO2（C1-6烷基），四唑-5-基，CONHSO2Ar3，CONHSO2（CH2）qAr3或CONHSO2（C1-6烷基）；Ar1-3独立地表示苯基，萘基或芳香杂环，这些基团可选地融合和可选地取代；Het1和Het2独立地表示非芳香杂环，可选地取代；在治疗再狭窄、肾衰竭和肺动脉高压方面具有用处。
• Indole derivatives useful as endothelin receptor antagonists
  申请人：——

  公开号：US20010014677A1

  公开（公告）日：2001-08-16

  1 Compounds of formula (I), and their pharmaceutically acceptable derivatives, wherein R 1 and R 2 are optional substituents and independently represent C 1-6 alkyl, C 2-6 alkenyl, optionally substituted by CO 2 H or CO 2 (C 1-6 alkyl), C 2-6 alkynyl, halogen, C 1-3 perfluoroalkyl, (CH 2 ) m Ar 1 , (CH 2 ) m Het 1 , (CH 2 ) m CONR 7 R 8 , (CH 2 ) m CO 2 R 8 , O(CH 2 ) q CO 2 R 8 , (CH 2 ) m COR 8 , (CH 2 ) m OR 8 , O(CH 2 ) p OR 8 , (CH 2 ) m NR 7 R 8 , CO 2 (CH 2 ) q NR 7 R 8 , (CH 2 ) m CN, S(O) n NR 8 , SO 2 NR 7 R 8 , CONH(CH 2 ) m Ar 1 or CONH(CH 2 ) m Het 1 ; R 3 represents H, C 1-6 alkyl, (CH 2 ) p NR 9 R 10 , SO 2 R 10 , SO 2 NR 9 R 10 , (CH 2 ) m CO 2 R 10 , C 2-6 alkenyl, C 2-6 alkynyl (CH 2 ) m CONR 9 R 10 , (CH 2 ) m CO 2 R 10 , (CH 2 ) p CN, (CH 2 ) p R 10 or (CH 2 ) p OR 10 ; R 4 represents H or C 1-6 alkyl; R 5 represents H or OH; R 6 represents phenyl optionally fused to a heterocyclic ring, the group as a whole being optionally substituted; R 7-10 are fully defined herein and may independently represent Ar 2 or Het 2 ; Z represents CO 2 H, CONH(tetrazol-5-yl), CONHSO 2 O(C 1-4 alkyl), CO 2 Ar 3 , CO 2 (C 1-6 alkyl), tetrazol-5-yl, CONHSO 2 Ar 3 , CONHSO 2 (CH 2 ) q Ar 3 or CONHSO 2 (C 1-4 alkyl); Ar 1-3 independently represent phenyl, naphthyl, or an aromatic heterocycle, which groups are optionally fused and optionally substituted; and Het 1 and Het 2 independently represent a non-aromatic heterocycle which is optionally substituted; are useful in the treatment of restenosis, renal failure and pulmonary hypertension.

  式（I）的化合物及其药学上可接受的衍生物，其中R1和R2是可选的取代基，且独立地表示C1-6烷基，C2-6烯基，可选地被CO2H或CO2（C1-6烷基）取代的C2-6炔基，卤素，C1-3全氟烷基，（CH2）mAr1，（CH2）mHet1，（CH2）mCONR7R8，（CH2）mCO2R8，O（CH2）qCO2R8，（CH2）mCOR8，（CH2）mOR8，O（CH2）pOR8，（CH2）mNR7R8，CO2（CH2）qNR7R8，（CH2）mCN，S（O）nNR8，SO2NR7R8，CONH（CH2）mAr1或CONH（CH2）mHet1；R3表示H，C1-6烷基，（CH2）pNR9R10，SO2R10，SO2NR9R10，（CH2）mCO2R10，C2-6烯基，C2-6炔基，（CH2）mCONR9R10，（CH2）mCO2R10，（CH2）pCN，（CH2）pR10或（CH2）pOR10；R4表示H或C1-6烷基；R5表示H或OH；R6表示苯环，可选地融合到杂环上，整个基团可选地被取代；R7-10在此完全定义，可以独立地表示Ar2或Het2；Z表示CO2H，CONH（四唑-5-基），CONHSO2O（C1-4烷基），CO2Ar3，CO2（C1-6烷基），四唑-5-基，CONHSO2Ar3，CONHSO2（CH2）qAr3或CONHSO2（C1-4烷基）；Ar1-3独立地表示苯环，萘环或芳香杂环，这些基团可以可选地融合和可选地被取代；Het1和Het2独立地表示可选地被取代的非芳香杂环；在治疗再狭窄，肾衰竭和肺动脉高压方面有用。
• 3-SUBSTITUTED-6-ARYL PYRIDINES
  申请人：Hutchinson Alan J.

  公开号：US20110281837A1

  公开（公告）日：2011-11-17

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I的3-取代-6-芳基吡啶化合物：其中R1、R2、R3、R8、R9、A和Ar的定义在此处。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及将这些化合物用于治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体定位的探针。
• 3-Substituted-6-Aryl Pyridines
  申请人：Hutchison Alan J.

  公开号：US20090176980A1

  公开（公告）日：2009-07-09

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I中的3-取代-6-芳基吡啶化合物： 其中R1、R2、R3、R8、R9、A和Ar在此定义。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的药物组合物，以及在治疗各种炎症，心血管和免疫系统疾病中使用这些化合物的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体的定位探针。
• INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS
  申请人：PFIZER INC.

  公开号：EP0901470A1

  公开（公告）日：1999-03-17